Drug Approvals of 2004
We review new drugs approved by the FDA in 2004, and the ratio of those developed internally to those that were in-licensed.
You may also be interested in...
Bayer's retreat from the global, primary-care stage into the mid-sized, regionally-focused specialist player arena was forced upon it by its own particular set of challenges. But other drug firms facing similar issues should take note: globalism may not be the best way forward in today's environment.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.